Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS · Delayed Price · Currency is USD
5.44
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Nxera Pharma Employees
Nxera Pharma had 384 employees as of September 30, 2025. The number of employees increased by 12 or 3.23% compared to the same quarter last year.
Employees
384
Change
12
Growth
3.23%
Revenue / Employee
$505,035
Profits / Employee
-$108,116
Market Cap
517.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 384 | 12 | 3.23% |
| Jun 30, 2025 | 389 | 29 | 8.06% |
| Mar 31, 2025 | 387 | 23 | 6.32% |
| Dec 31, 2024 | 374 | 24 | 6.86% |
| Sep 30, 2024 | 372 | 24 | 6.90% |
| Jun 30, 2024 | 360 | 149 | 70.62% |
| Mar 31, 2024 | 364 | 157 | 75.85% |
| Dec 31, 2023 | 350 | 148 | 73.27% |
| Sep 30, 2023 | 348 | 149 | 74.87% |
| Jun 30, 2023 | 211 | 6 | 2.93% |
| Mar 31, 2023 | 207 | 10 | 5.08% |
| Dec 31, 2022 | 202 | 4 | 2.02% |
| Sep 30, 2022 | 199 | 3 | 1.53% |
| Jun 30, 2022 | 205 | 17 | 9.04% |
| Mar 31, 2022 | 197 | 4 | 2.07% |
| Dec 31, 2021 | 198 | 8 | 4.21% |
| Sep 30, 2021 | 196 | 12 | 6.52% |
| Jun 30, 2021 | 188 | 18 | 10.59% |
| Mar 31, 2021 | 193 | 30 | 18.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
Nxera Pharma News
- 4 weeks ago - Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P. - Seeking Alpha
- 4 weeks ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 5 weeks ago - Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties - GlobeNewsWire
- 7 weeks ago - Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia - GlobeNewsWire
- 3 months ago - Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan - GlobeNewsWire
- 3 months ago - Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript - Seeking Alpha
- 3 months ago - Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel - GlobeNewsWire
- 3 months ago - Nxera Announces Focused Restructuring to Enhance Path to Profitability - GlobeNewsWire